Like transcription factor MYC [36] and chromatin regulator PBRM1 [37], which are reported to determine the sensitivity of PD-1 blockade therapy showed no difference between MSI and MSS colon cancer patients in mRNA expression level. This evidence concerns the gene PBRM1 and colonic neoplasm.